PharmAsia Summit 2010

Windhover Conferences presents PharmAsia Summit 2010

Register now for the most strategic-level meeting where senior biotech and pharma executives share real-life case studies on how they're building a presence in Asia - from drug development to market.

October 25-26, 2010
InterContinental Mark Hopkins, San Francisco
www.windhover.com/PharmAsiaSummit

Taking the Risk out of Asia: Top Pharma Leaders Share Best Practices

This year's PharmAsia Summit brings Asian, US and European industry leaders to San Francisco to share their experiences and help those already involved in Asian operations or planning Asia strategies to better understand the myriad of complex challenges and equally attractive opportunities facing them. Early Bird Registration Ends Sept. 30th so register today!
PharmAsia Summit is the only event featuring marquee-level speakers and topics, including:

Catch Up on the Latest Asian Market Trends and Data
Jan Willem Eleveld, VP Consulting & Services Asia Pacific, IMS Management Consulting

Perspective: Opportunities and Challenges In Asia - Biogen Idec's Strategy in Asia
Gunther Winkler, PhD, SVP Asia Pacific & Global Government Strategy, Biogen Idec

Betting on Different Models of Innovation in China: New Paths to New Products
TJ Deng, General Manager & VP of Emerging Business and Product Development, BioDuro, a PPD company
Li Chen, PhD, former Head of Research & CSO, Roche R&D Center China
Mike F. Gordeev, PhD, Chief Scientific Officer, MicuRx Pharmaceuticals, Inc.
Jimmy Z. Zhang, PhD, MBA, SVP, Synergenics

The Asia Strategy for a Biotech Company: What is the Right Kind of Deal?
Jan-Anders Karlsson, PhD, CEO, S*Bio
Anthony Coles, MD, MPH, CEO, Onyx Pharmaceuticals
Carl Firth, CEO, ASLAN Pharmaceuticals
Thomas Slater, VP Commercial Development & International, Cubist Pharmaceuticals

Lessons Learned in Outsourcing: How Much Risk is Too Much?
Simon Britton, Head of Clinical Development Asia, PPD
Anand Tharmratnam, MD, MRCA, VP, Quintiles Asia Pacific
Darren Ji, MD, PhD, MBA, CEO, PharmaLegacy
Leslie Platt, Esq. (moderator), Member, PharmAsia News Editorial Advisory Board

Grasping the Ins and Outs of Pricing, Market Access, IP & Dealmaking in India
Somesh Sharma, PhD, Managing Director, Piramal Life Sciences
Gary Deeb, VP Business Development, Glenmark Pharmaceuticals
Dr Deven Parmar, MD, Vice President - Clinical Research, Wockhardt

FDA Abroad: Insight From U.S. FDA Directors
Bruce Ross, India Office Director, U.S. FDA
Chris Hickey, China Office Director, U.S. FDA

Beyond Cost Arbitrage and More Shots on Goal: India Opportunity for Innovation
Rashmi H. Barbhaiyam, CEO & Managing Director, Advinus Therapeutics

Case Studies on New Models for Japanese Dealmaking
Jim Toole, Senior Director, Oncology New Product Planning, Daiichi Sankyo 
John Celebi, VP Business Development New Products, & Alliance Management, ArQule Inc.
George Montgomery (moderator), Managing Director, Montgomery Marshall Healthcare Partners

Regulatory Risks: Drug Safety & Post-Market Surveillance
Yi Chengdong, Deputy Director-General, Shanghai FDA
Kyuhan Chae, Deputy Director Of Pharmaceutical Safety, Korea FDA

Big Pharma Perspective: Comparing Emerging Markets Strategies: Acquisition vs. Organic growth?
Ramesh Subrahmanian, SVP & President of Asia Pacific Human Health, Merck & Co., Inc.

Investment Outlook For Asia: What Bets Should You Make?
Jonathan Wang, PhD, MBA, Senior Managing Director, Asia, OrbiMed Advisors
Graeme Martin, PhD, President & CEO, Takeda Research Investment
Charles Hsu, PhD, MBA, Partner, Bay City Capital
Utkarsh Palnitkar, Executive Director, Centrum Capital
Ravi Kiron (moderator), Managing Director, Adjuvant Global Advisors

Commercializing Your Drug in Asia: Case Studies on Marketing Authorization, Pricing, and Market Access
Sanjiv Navangul, MBA, MSD, Director - Chronic Care, Specialty Care, Disease Management India, Merck & Co., Inc.
Rhee Byung Geon, CEO, Green Cross

Pre-competitive Collaboration in Asia - A New Model for Sharing Risks, Reaping Rewards
Neil W. Gibson, PhD, Chief Scientific Officer, Oncology Research, Pfizer
Don Joseph, COO, BIO Ventures for Global Health
David Perry, CEO, Anacor Pharmaceuticals
Gail Cassell, PhD, VP, Scientific Affairs & Distinguished Research Scholar for Infectious Diseases, Eli Lilly & Company

China Healthcare Reform:  What Comes Next?
Hongbo Lu, PhD, VP & Senior Research Analyst - China Healthcare, Piper Jaffray
Katherine Wang, Counsel, Sidley Austin and Former Asia General Counsel, AstraZeneca
Helen Chen (moderator), China Practice Leader, LEK Consulting and Member, PharmAsia News Editorial Advisory Board

2010 Sponsors

Global Sponsor: IMS Health
Gold Sponsor: PPD, Morrison Foerster
Silver Sponsor: Gerson Lehrman Group
Regional Partners & Supporting Organizations: BayBio, BayHelix, USA-India Chamber of Commerce, Chinese - American BioPharmaceutical Society, California Healthcare Institute, ChinaSF, ABLE, BIOTECanada, Korea Health Industry Development Institute
Association Sponsors: Licensing Executives Society, Sino-American Biomedical and Pharmaceutical Professionals Association
Media Partners: Current Partnering, pharmalicensing.com, The PharmYard, Pharma Connections, goBalto, ANGEL NEWS

Further details can be found online at www.windhover.com/PharmAsiaSummit.